TARRYTOWN, N.Y., Oct. 15 /PRNewswire-FirstCall/ — Regeneron
Pharmaceuticals, Inc. (Nasdaq:
REGN) will webcast its presentation at the 17th Annual
NewsMakers in the Biotech Industry Conference on Friday, October
22, 2010. The presentation is scheduled for 9:00 a.m. Eastern
Time. The session may be accessed through the Company’s web
site, www.regeneron.com, on the
Investor Relations page. An archived version of the
presentation will be available after the live webcast through
November 21, 2010.
Regeneron is a fully integrated biopharmaceutical company that
discovers, develops, and commercializes medicines for the treatment
of serious medical conditions. In addition to ARCALYST®
(rilonacept) Injection for Subcutaneous Use, its first
commercialized product, Regeneron has therapeutic candidates in
Phase 3 clinical trials for the potential treatment of gout,
diseases of the eye (wet age-related macular degeneration and
central retinal vein occlusion), and certain cancers.
Additional therapeutic candidates developed from proprietary
Regeneron technologies for creating fully human monoclonal
antibodies are in earlier stage development programs in rheumatoid
arthritis and other inflammatory conditions, pain, cholesterol
reduction, allergic and immune conditions and cancer.
Additional information about Regeneron and recent news
releases are available on Regeneron’s web site at www.regeneron.com. Contact
Information:Michael Aberman, M.D.
Peter DworkinInvestor Relations